Genmab A/S (NASDAQ:GMAB) Given “Buy” Rating at Truist Financial

Truist Financial restated their buy rating on shares of Genmab A/S (NASDAQ:GMAB) in a report published on Tuesday, Benzinga reports. They currently have a $50.00 price target on the stock.

A number of other brokerages also recently issued reports on GMAB. Citigroup downgraded shares of Genmab A/S from a neutral rating to a sell rating in a research report on Monday, January 22nd. BMO Capital Markets raised shares of Genmab A/S from a market perform rating to an outperform rating and upped their price objective for the stock from $46.00 to $48.00 in a research report on Friday, February 23rd. UBS Group upgraded shares of Genmab A/S from a neutral rating to a buy rating in a research note on Wednesday, December 6th. Finally, HC Wainwright reiterated a buy rating and issued a $50.00 target price on shares of Genmab A/S in a research note on Wednesday, March 6th. Three analysts have rated the stock with a sell rating, two have issued a hold rating and eight have given a buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of Hold and a consensus price target of $48.50.

Genmab A/S Price Performance

NASDAQ:GMAB opened at $29.91 on Tuesday. The firm has a 50-day moving average of $28.88 and a 200-day moving average of $31.09. The company has a market cap of $19.76 billion, a PE ratio of 31.16, a PEG ratio of 1.44 and a beta of 0.98. Genmab A/S has a one year low of $26.32 and a one year high of $42.99.

Genmab A/S (NASDAQ:GMAB) last posted its earnings results on Wednesday, February 14th. The company reported $0.36 EPS for the quarter, topping the consensus estimate of $0.34 by $0.02. Genmab A/S had a net margin of 26.50% and a return on equity of 18.06%. The company had revenue of $675.29 million during the quarter, compared to the consensus estimate of $678.14 million. On average, equities research analysts expect that Genmab A/S will post 1.09 earnings per share for the current fiscal year.

Institutional Trading of Genmab A/S

A number of institutional investors have recently modified their holdings of GMAB. JPMorgan Chase & Co. lifted its stake in shares of Genmab A/S by 42.7% during the 1st quarter. JPMorgan Chase & Co. now owns 135,116 shares of the company’s stock valued at $4,889,000 after buying an additional 40,444 shares in the last quarter. Bank of New York Mellon Corp lifted its stake in Genmab A/S by 4.2% in the 1st quarter. Bank of New York Mellon Corp now owns 116,847 shares of the company’s stock worth $4,227,000 after purchasing an additional 4,665 shares in the last quarter. Private Advisor Group LLC lifted its stake in Genmab A/S by 24.0% in the 1st quarter. Private Advisor Group LLC now owns 20,119 shares of the company’s stock worth $728,000 after purchasing an additional 3,891 shares in the last quarter. BlackRock Inc. lifted its stake in Genmab A/S by 1.6% in the 1st quarter. BlackRock Inc. now owns 5,494,689 shares of the company’s stock worth $198,799,000 after purchasing an additional 86,571 shares in the last quarter. Finally, Dimensional Fund Advisors LP increased its holdings in shares of Genmab A/S by 18.1% in the 1st quarter. Dimensional Fund Advisors LP now owns 18,243 shares of the company’s stock worth $660,000 after buying an additional 2,792 shares during the last quarter. 7.07% of the stock is currently owned by hedge funds and other institutional investors.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.